Screening for antibacterial inhibitors of the UDP-3-O-(R-3- Hydroxymyristoyl)-N-Acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assay

Journal of Biomolecular Screening

Volumn 15, Issue 1, 2010, Pages 62-71

  Langsdorf, Erik F ^a,c   Malikzay, Asra ^a   Lamarr, William A ^b   Daubaras, Dayna ^a,d   Kravec, Cynthia ^a   Zhang, Rumin ^a   Hart, Richard ^a   Monsma, Frederick ^a   Black, Todd ^a   Ozbal, Can C ^b   Miesel, Lynn ^a   Lunn, Charles A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BioTrove Inc   (United States)

^c SETON HALL UNIVERSITY   (United States)

^d IDAHO NATIONAL LABORATORY   (United States)

Author keywords

Label free; Mass spectrometry; Thermal stability shift; UDP 3 O (R 3 Hydroxymyristoyl) N acetylglucosamine deacetylase (LpxC)

Indexed keywords

ANTIBIOTIC AGENT; BACTERIUM LIPOPOLYSACCHARIDE; ENZYME INHIBITOR; PLASMID DNA; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE; URIDINE DIPHOSPHATE O (3 HYDROXYMYRISTOYL) N ACETYLGLUCOSAMINE DEACETYLASE;

ANTIBACTERIAL ACTIVITY; ARTICLE; ASSAY; BACTERIAL GROWTH; BACTERIUM CULTURE; BIOSYNTHESIS; CATALYSIS; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HIGH THROUGHPUT SCREENING; MASS SPECTROMETER; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TECHNOLOGY; THERMOSTABILITY;

ESCHERICHIA COLI; NEGIBACTERIA;

EID: 77949363962     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057109352902     Document Type: Article

References (24)

1. Onishi HR, Pelak BA, Gerekens LS, Silver LL, Kahan FM, Chen MH, et al: Antibacterial agents that inhibit lipid A biosynthesis. Science 1996 274 980-982.
2. Clements JM, Coignard F, Johnson I, Chandler S, Palan S, Waller A, et al: Antibacterial activities and characterization of novel inhibitors of LpxC. Antimicrob Agents Chemother 2002 46 1793-1799.
3. McClerren AL, Endsley S, Bowman JL, Andersen NH, Guan Z, Rudolph J, et al: A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin. Biochemistry 2005 44 16574-16583.
4. Barb AW, Zhou P: Mechanism and inhibition of LpxC: an essential zincdependent deacetylase of bacterial lipid A synthesis. Curr Pharm Biotechnol 2008 9 9-15.
5. Jackman JE, Raetz CR, Fierke CA: UDP-3-O-(R-3-Hydroxymyristoyl)-N- acetylglucosamine deacetylase of Escherichia coli is a zinc metalloenzyme. Biochemistry 1999 38 1902-1911.
6. Anzellotti AI, Farrell NP: Zinc metalloproteins as medicinal targets. Chem Soc Rev 2008 37 1629-1651.
7. Puerta DT, Cohen SM: A bioinorganic perspective on matrix metalloproteinase inhibition. Curr Top Med Chem 2004 4 1551-1573.
8. Hyland SA, Eveland SS, Anderson MS: Cloning, expression, and purification of UDP-3-O-acyl-GlcNAc deacetylase from Pseudomonas aeruginosa: a metalloamidase of the lipid A biosynthesis pathway. J Bacteriol 1997 179 2029-2037.
9. Jackman JE, Fierke CA, Tumey LN, Pirrung M, Uchiyama T, Tahir SH, et al: Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria: inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs. J Biol Chem 2000 275 11002-11009.
10. Wang W, Maniar M, Jain R, Jacobs J, Trias J, Yuan Z: A fluorescencebased homogeneous assay for measuring activity of UDP-3-0-(Ähydroxymyristoyl)-N- acetylgluocosamine deactylase. Anal Biochem 2001 290 338-1334
11. Shiau AK, Massari ME, Ozbal CC: Back to basics: label-free technologies for small molecule screening. Comb Chem High Throughput Screen 2008 11 231-237.
12. Ozbal CC, LaMarr WA, Linton JR, Green DF, Katz A, Morrison TB, et al: High throughput screening via mass spectrometry: a case study using acetylcholinesterase. Assay Drug Dev Technol 2004 2 373-381.
13. Lo MC, Aulabaugh A, Jin G, Cowling R, Bard J, Malamas M, et al: Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal Biochem 2004 332 153-159.
14. Sheets MP, Warrior UP, Yoon H, Mollison KW, Djuric SW, Trevillyan JM: A high-capacity scintillation proximity assay for the discovery and evaluation of ZAP-70 tandem SH2 domain antagonists. J Biomol Screen 1998 3 139-144.
15. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 4 67-73.
16. Young K, Silver LL: Leakage of periplasmic enzymes from envAl strains of Escherichia coli. J Bacterial 1991 173 3609-3614.
17. Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, Caldwell SD, et al: Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 2005 280 17038-17045.
18. Borra MT, Smith BC, Denu JM: Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005 280 17187-17195.
19. Zehender H, Mayr LM: Application of mass spectrometry technologies for the discovery of low-molecular weight modulators of enzymes and protein-protein interactions. Curr Opin Chem Biol 2007 11 511-517.
20. Quercia AK, LaMarr WA, Myung J, Ozbal CC, Landro JA, Lumb KJ: High-throughput screening by mass spectrometry: comparison with the scintillation proximity assay with a focused-file screen of AKT1/PKBa. J Biomol Screen 2007 12 473-480.
21. Feng BY, Shoichet BK: Synergy and antagonism of promiscuous inhibition in multiple-compound mixtures. J Med Chem 2006 49 2151-2154.
22. Ferrand S, Schmid A, Engeloch C, Glickman JF: Statistical evaluation of a self-deconvoluting matrix strategy for high-throughput screening of the CXCR3 receptor. Assay Drug Dev Technol 2005 3 413-424.
23. Turek-Etienne TC, Small EC, Soh SC, Xin TA, Gaitonde PV, Barrabee EB, et al: Evaluation of fluorescent compound interference in 4 fluorescence polarization assays: 2 kinases, 1 protease, and 1 phosphatase. J Biomol Screen 2003 8 176-184.
24. Motlekar N, Diamond SL, Napper AD : Evaluation of an orthogonal pooling strategy for rapid high-throughput screening of proteases. Assay Drug Dev Technol 2008 6 395-405.